A pharma industry event round-up: Insights and trends
![A pharma industry event round-up: Insights and trends](/sites/default/files/styles/x_large/public/2023-09/A-pharma-industry-event-round-up-1200x675.jpg?itok=xB5lBzJf)
From artificial intelligence and digital therapeutics to the latest in oncological research and RNA therapeutics, from developments in the CNS field to what’s what in customer experience and pharma marketing, many of the events that pharmaphorum has covered in 2023 presented a broad spectrum of insights and telling suggestion of future trends to come. Here are some snippets of the most memorable conversations from Pharma Integrates, BIO-Europe Spring, NEXT Pharma, and RNA Therapeutics.
1. Pharma Integrates, London
Before we delve into the most noteworthy talking points from pharmaphorum’s 2023 event coverage, it is worth exploring some of the predictions, trends, and industry issues that proceeded the arrival of the new year.
The ‘Big C’ proved to be a key talking point during Pharma Integrates London at the close of 2022. In a panel moderated by Linda Summerton, head of scientific affairs and oncology at Transcript, Jane Robertson, chief medical officer at Redx Pharma, reported noticeable progress in cervical, breast, and prostate cancer screening, but noted that more collaboration with academia and industry partners was needed to better identify high-risk patients and those who need a specific, directed screening programme.
Renata Crome, trustee, non-executive director, and pharmaceutical development advisor at PTEN research foundation, noted that the ‘needle has moved’, but not always in the right direction. Indeed, a lot more is now known about the effects on mental health and anxiety in the cancer care pathway, including the trauma of multiple biopsies.
• Read the full article in pharmaphorum's Deep Dive digital magazine